Spike protein doesn’t always leave.

It is the surface protein SARS-CoV-2 uses to bind human cells. You get it two ways: the virus brings it, and an mRNA or adenoviral-vector vaccine instructs your own cells to make it. Reviewers describe the same inflammatory pathways behind Long COVID and post-vaccine symptoms, because it is the same protein either way.

Longer than weeks in some people. Two documented case histories found circulating spike protein with elevated anti-spike antibodies three and a half years after vaccination, alongside multisystem symptoms. In mice, the lipid nanoparticle carrier persisted in tissue for weeks, concentrating in liver and spleen, while spike production peaked within hours.

Infection makes spike protein too. The persistence research covers both routes, and the tissue effects in the studies do not depend on where the protein came from.

Specialist laboratories run assays for circulating spike and anti-spike antibodies, and that is what the published case histories used. A 2025 review states that medicine still lacks a definitive diagnostic test for post-vaccination syndrome, so a number from one of these assays is a data point rather than a diagnosis. The free Lab Library explains what each marker does and does not tell you.

In the published work it activates brain microglia and mast cells and damages the blood-brain barrier, raises MMP-9, binds MAO-B and impairs mitochondrial energy production in neuron-like cells, drives adhesion molecules and an inflammatory state in human endothelial cells, triggers platelet aggregation, and aggregates inside human heart-muscle cells.

Each mRNA dose instructs cells to produce spike again, which is how the vaccine works. The persistence research is about how long the protein and its carrier remain after that production stops.

The alpha-7 nicotinic acetylcholine receptor is the switch on the vagus nerve that tells the immune system to stand down. Research groups report SARS-CoV-2 interacting with that receptor, which would disrupt the reflex that restrains cytokine release. In Long COVID, low-dose transcutaneous nicotine restored nicotinic receptor availability and relieved symptoms in 73.5 percent of participants. This formula aims at that pathway through botanicals, with lobeline as the nicotinic active.

A 1 ml proprietary blend in a 2 fl oz bottle: lobelia, licorice, mucuna, lemon balm and citicoline, with CO2 extracts of lobelia, wormwood, licorice, lemon balm, mucuna and cinnamon, plus a superconductive liquid gold, supercharged C60 and Cu1, in a glycerin and structured water base. $46.95. The full panel as printed is on the product card.

Ryan toured the Houston facility. The water for the tinctures never touches plastic, running through platinum and silicone instead. Extraction is cold-pressed only, in glass. Every batch is tested for pesticides, mold and residual chemicals, not just potency. Solfeggio frequencies play over the room during production.

No code is needed. The Global Healing link carries our referral, so you pay the same price as going direct. We earn a referral commission at no cost to you. Education only, not medical advice.